NASDAQ$BBNX
Beta Bionics Inc · Q2 2025 earnings
Q2 2025 earnings ·
Briefing
Beta Bionics reported Q2 2025 revenue of $23.2M, a net loss of $16.9M, diluted EPS of $-0.39.
For Q2 2025, Beta Bionics reported Revenue was $23.2M, net loss was $16.9M, diluted EPS was $-0.39. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $23.2M for Q2 2025.
- Net loss $16.9M.
- Diluted EPS $-0.39.
Headline financials
Revenue & EPS history
Beta Bionics Inc · Revenue · Quarterly
$23.2M
Forward guidance
Healthcare and biotech outlook emphasizes pipeline milestones and cash runway.
Tailwinds
- Clinical data and partnership economics.
- Cost discipline and prioritized programs.
Headwinds
- Trial, regulatory, and reimbursement risk.
- Operating losses until commercial scale.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q2 2025
-0.7%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+18.0%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+4.8%
Q2 2025
Best reaction
-5.0%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.0% | -13.5% | -17.7% | |
| Q4 2025 | -2.6% | -1.5% | -23.4% | |
| Q3 2025 | +2.2% | +14.6% | +29.9% | |
| Q2 2025 | +4.8% | +17.2% | +33.7% | |
| Q1 2025 | -2.8% | +19.4% | +67.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro